AstraZeneca Plc and Oxford University have resumed clinical trials in the UK for their candidate Covid-19 vaccine following a pause earlier this month triggered by an adverse event. The event led to a voluntary stoppage of vaccination across all global trials to allow for a review of safety data by independent committees and international regulators.
On 12 September, AstraZeneca and Oxford announced that the UK regulator had ruled that it was safe to continue trials in the UK. Further details about the case were not disclosed.